Structured evidence table for Carnitine Mood Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Carnitine Mood Randomized Trial | because of evidence of its use by athletes with the intention of enhancing performance The World Anti-Doping Agency (WADA) classified Meldonium as a prohibited substance effective January 1, 2016. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Carnitine Mood Randomized Trial | The decision to move Meldonium from the Monitoring program to the Prohibited list was made “…” (WADA 2016 Prohibited List, 16 September 2015), rather than robust scientific evidence demonstrating actual performance enhancement. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Carnitine Mood Randomized Trial | To date, scientific consensus on Meldonium’s ergogenic effects in humans remains inconclusive, prompting a need for a critical evaluation of the existing evidence hierarchy. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Carnitine Mood Randomized Trial | 1 2 β While Western countries commonly refer to substances like Meldonium as “metabolic modulators,” in Eastern countries, they are frequently classified as “antihypoxic agents” (). | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
Source documents